Novartis Earnings: Patent Cliff Edition

With another earnings season upon us, The Fool's health care team is busy making sure investors know what to expect from their favorite companies this quarter, while also maintaining a focus on the long term.

In this segment, health care bureau chief Brenton Flynn tells us what to expect with Novartis , which reports quarterly results on Wednesday. While the top line will likely experience a dip, Brenton likes what the company has done to keep costs low as it faces increased generic competition for its top-selling drug Diovan. He also highlights two of the company's newer drugs that he'll be keeping a close eye on, one of which should be of particular interest to Regeneron shareholders.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Novartis Earnings: Patent Cliff Edition originally appeared on Fool.com.

Brenton Flynn and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.